• Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage S... 6/26/2023
• Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivol... 6/19/2023
• Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th... 5/31/2023
• Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023 1/4/2023
• Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Tria... 12/13/2022
• Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rig... 11/8/2022
• Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022 11/3/2022
• Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia... 9/15/2022
• Tessa Therapeutics Appoints Thomas Willemsen as President and CEO 8/22/2022
• Tessa Therapeutics to Host Scientific Session on CD30 CAR-T Targeting of CD30+ Lymphomas a... 6/14/2022